** Shares of medtech co Zynex ZYXI.O fall 14.7% to $5.97 aftermarket
** Reports Q4 net revenue of $46 mln compared to $47.3 mln a year ago
** Says that the revenue shortfall was due to slower-than-normal payments from certain payers as well as a temporary suspension of payments from healthcare service provider Tricare
** Co says TriCare represents about 20%-25% of annual revenue
** Says due to the temporary payment suspension, co is cutting jobs by about 15%
** The staff reduction along with other expense reductions will result in savings of about $35 mln annually — ZYXI
** Co expects Q1 2025 net revenue of at least $30 mln vs estimates of $53.5 mln — LSEG data
** Stock has fallen 26.5% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。